Incyte nabs approval of topical ruxolitinib in atopic dermatitis, but gets slapped with JAK warning
Incyte has made a pretty penny with its JAK inhibitor ruxolitinib over the years, but on Tuesday the drug crossed a new threshold.
The FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
